Availability of Specific Direct Oral Anticoagulant Reversal Agents in US Hospitals
Zahir Kanjee, Marissa McCann, Jason A. Freed
Abstract
This cross-sectional study assesses the availability of the direct oral anticoagulant reversal agents idarucizumab and andexanet alfa in US hospitals.
Topics & Concepts
IdarucizumabOral anticoagulantAnticoagulantMedicineIntensive care medicineRisk analysis (engineering)BusinessDabigatranSurgeryInternal medicineWarfarinAtrial fibrillationAtrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and ManagementAntiplatelet Therapy and Cardiovascular Diseases